TNFSF11 and Fabry disease: RANKL expression is increased in FD lesions and some previous studies have shown that RANKL inhibition, achieved either by RANKL neutralizing antibody [29, 30] or small-molecule RANKL inhibitor [75], is effective in modifying the pathology and natural history of the disease, offering potential benefits to patients, especially those with early onset of FD.